<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0308233951
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INSTIGAR 30 mg Delayed-Release Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEXLANSOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        30.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Instigar contains the active substance dexlansoprazole, which is a proton pump inhibitor (PPI). PPIs reduce the amount of acid that your stomach makes.</p><p>Instigar is used in adults and adolescents aged 12 years and above for the following:</p><ul><li>Treatment of erosive reflux oesophagitis (inflammation with damage to the lining of the oesophagus (food pipe))</li><li>Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn</li><li>Short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD). GORD is a condition where stomach acid leaks out of the stomach and comes up into the oesophagus (acid reflux).</li></ul><p>By reducing the amount of stomach acid Instigar can heal the damage of the oesophagus and relieve symptoms that can happen with the above conditions and stop them from coming back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Instigar</strong></p><ul><li>If you are allergic to dexlansoprazole or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor before taking or while you are taking Instigar:</p><ul><li>If you have liver problems. Your doctor may have to adjust your dosage.</li><li>If you have stomach problems. Your doctor may perform an additional investigation called an endoscopy (where a very small camera is inserted down your oesophagus to look into your stomach), which can help to exclude more serious causes of your symptoms.</li><li>If you take a proton pump inhibitor like Instigar, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis (reduced bone density) or if your doctor has told you that you are at risk of getting osteoporosis (for example, if you are taking steroids).</li><li>If you take Instigar on a long-term basis (longer than 1 year). Your doctor will probably ask to see you regularly so he can check how well you are doing. Tell your doctor if you notice any new symptoms or if any of your symptoms are getting worse.</li><li>If you take other medicines such as digoxin (for the treatment of heart problems) or diuretics (&lsquo;water tablets&rsquo;). Your doctor will probably monitor the magnesium levels in your blood periodically.</li><li>If you have low vitamin B<sub>12</sub> levels or have risk factors for low vitamin B<sub>12</sub> levels and receive long-term treatment with Instigar. As with all acid reducing agents, Instigar may lead to a reduced absorption of vitamin B<sub>12</sub>.</li><li>If you have ever had a skin reaction after treatment with a medicine similar to Instigar that reduces stomach acid.</li><li>&nbsp;If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Instigar. Remember to also mention any other ill-effects like pain in your joints.</li><li>When taking dexlansoprazole, inflammation in your kidney may occur. Signs and symptoms may include decreased volume of urine or blood in your urine and/or hypersensitivity reactions such as fever, rash, and joint stiffness. You should report such signs to the treating physician.</li><li>Dexlansoprazole can cause rare but severe skin reactions that may affect any part of your body (see also section 4). These serious skin reactions may need to be treated in a hospital and may be life threatening; Skin rash which may have blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet). You may also have fever, chills, body aches, shortness of breath, or enlarged lymph nodes. Stop taking Instigar and call your doctor right away. These symptoms may be the first sign of a severe skin reaction.</li><li>If you are due to have a specific blood test (Chromogranin A).</li></ul><p><strong>Children</strong><br />Do not give this medicine to children under 12 years.</p><p><strong>Other medicines and Instigar</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines. This is because dexlansoprazole can affect the way some other medicines work. Also, some medicines can affect the way dexlansoprazole works.</p><p>Check with your doctor before taking Instigar if you are taking any of the following medicines:</p><ul><li>HIV protease inhibitors such as atazanavir and nelfinavir (to treat HIV)</li><li>Ketoconazole, itraconazole, rifampicin (to treat infections)</li><li>Erlotinib (to treat cancer)</li><li>Digoxin (to treat heart problems)</li><li>Tacrolimus (to prevent transplant rejection)</li><li>Fluvoxamine (to treat depression and other psychiatric diseases)</li><li>Warfarin (to prevent thrombosis)</li><li>Antacids (to treat heartburn or acid regurgitation)</li><li>Sucralfate (for healing ulcers)</li><li>St John&rsquo;s wort (Hypericum perforatum)<em> </em>(to treat mild depression)</li><li>Methotrexate (to treat cancer)</li></ul><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p><strong>Driving and using machines</strong><br />Side effects such as dizziness, vertigo, tiredness and visual disturbances sometimes occur in patients taking dexlansoprazole. If you experience side effects like these, you should take caution as your ability to react may be decreased.</p><p>You alone are responsible to decide if you are in a fit condition to drive a motor vehicle or perform other tasks that demand increased concentration. Because of their effects or undesirable effects, one of the factors that can reduce your ability to do these things safely is your use of medicines.</p><p>Descriptions of these effects can be found in other sections.</p><p>Read all the information in this leaflet for guidance.</p><p>Discuss with your doctor if you are unsure about anything.</p><p><strong>Instigar contains sucrose</strong><br />Instigar contains sucrose. Each modified-release hard capsule of Instigar 30 mg and 60 mg Modified-release Hard Capsules contains 68 mg or 76 mg sucrose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Swallow the capsules whole with a glass of water. You can take the capsules with or without food. If you have trouble swallowing Instigar capsules whole, you can open the capsules and sprinkle the contents on a tablespoon of apple pur&eacute;e (such as apple sauce). Be sure to swallow the apple mixture right away. Do not chew the mixture. Do not store for later use.</p><p><strong>The recommended dose for adults is as follows:</strong></p><ul><li>Treatment of erosive reflux oesophagitis:<strong> </strong>take 60 mg once daily for 4 weeks. Your doctor may prescribe an additional 4 weeks.</li><li>Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn in patients where prolonged acid suppression is needed:<strong> </strong>take 30 mg once daily for up to 6<strong> </strong>months.</li><li>Treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD): take 30 mg once daily for up to 4 weeks.</li></ul><p><strong>The recommended dose for adolescents aged 12 to 17 years is as follows:</strong></p><ul><li>Treatment of erosive reflux oesophagitis: take 60 mg once daily for 4 weeks. Your doctor may prescribe an additional 4 weeks.</li><li>Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn in patients where prolonged acid suppression is needed: take 30 mg once daily. Your doctor will define total treatment time.</li><li>Treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD): take 30 mg once daily for up to 4 weeks.</li></ul><p><strong>Elderly and patients with liver problems: </strong>Your doctor may prescribe a lower dose.</p><p>Your doctor will advise you how long to take Instigar.</p><p>If necessary, your doctor may tell you to take a different dose.</p><p><strong>If you take more </strong><strong>Instigar than you should</strong><br />If you accidentally take multiple capsules (overdose), or if someone else takes multiple doses of your medicine at the same time, talk to a doctor immediately.</p><p>The following symptoms have been reported in patients who had taken large doses of dexlansoprazole:</p><ul><li>High blood pressure, hot flushes, bruises, throat pain and weight loss.</li></ul><p><strong>If you forget to take Instigar</strong><br />If you forget to take a dose, take it as soon as you remember unless it is nearly time for your next dose. If this happens, skip the missed dose and carry on with your next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Instigar</strong><br />Do not stop treatment early because you feel better. Your condition may not have been fully resolved and may return if you do not finish your course of treatment. Talk to your doctor before stopping this treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In clinical studies side effects associated with dexlansoprazole treatment were mostly mild or moderate.</p><p><strong>If you get any of the following side effects, stop taking these capsules and tell your doctor immediately, or contact the casualty department at your nearest hospital:</strong></p><ul><li>Hypersensitivity or serious allergic reactions (frequency not known) such as rash, face swelling, throat tightness, difficulty breathing</li><li>Anaphylactic shock or serious, severe and sudden allergic reaction (frequency not known) with symptoms such as shortness of breath, confusion, pale colour, severe skin eruptions, throat tightness, weakness, gasping for air and unconsciousness.</li></ul><p><strong>The most frequently reported side effects (common &ndash; may affect up to 1 in 10 people) were:</strong></p><ul><li>Diarrhoea, abdominal pain, headache, feeling sick (nausea), abdominal discomfort, gas (flatulence), constipation and benign polyps in the stomach.</li></ul><p><strong><em>Some patients experienced the following other side effects with dexlansoprazole:</em></strong><br /><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul><li>Difficulty in sleeping</li><li>Depression</li><li>Dizziness</li><li>Altered taste</li><li>High blood pressure</li><li>Hot flushes</li><li>Cough</li><li>Vomiting</li><li>Dry mouth</li><li>Liver function test abnormalities</li><li>Hives</li><li>Itching</li><li>Rash</li><li>Feeling of weakness</li><li>Appetite changes</li><li>Fracture of hip, wrist or spine</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><ul><li>Hallucinations involving the hearing of voices or sounds</li><li>Convulsion</li><li>Tingling or numbness</li><li>Visual disturbance</li><li>Feeling of dizziness or &ldquo;spinning&rdquo;</li><li>Yeast infections</li></ul><p><strong>&nbsp;Not known (frequency cannot be estimated from the available data):</strong></p><ul><li>Reduced number of red blood cells. This may cause paleness, weakness, intolerance to physical activity, dizziness, tiredness and confusion</li><li>Bruising or bleeding caused by abnormally low platelet count of unknown cause</li><li>Severe skin reactions (Stevens-Johnson syndrome), toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, and subacute cutaneous lupus erythematosus. You may also have joint pain or flu-like symptoms, a fever, swollen glands (e.g. in the armpit) and blood tests may show changes in certain white blood cells or liver enzymes</li><li>Blurred vision</li><li>Deafness</li><li>Hepatitis caused by medicines (with symptoms such as loss of appetite, headache, nausea, fatigue, fever, jaundice, pale or clay-coloured stools, dark urine)</li><li>Rash, possibly with pain in the joints</li><li>If you are on dexlansoprazole for more than three months, it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</li><li>Low levels of sodium in the blood. Common symptoms include nausea and vomiting, headache, drowsiness and fatigue, confusion, muscle weakness or spasms, irritability, seizures, coma.</li><li>Kidney problems</li><li>Visual hallucinations.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is dexlansoprazole.</p><p>Each modified-release hard capsule of Instigar 30 mg and 60 mg Modified-release Hard Capsules contains 30 mg or 60 mg dexlansoprazole; respectively.</p><p>The other ingredients are: <em>Capsule content:</em> Silica colloidal anhydrous, hydroxypropyl cellulose, hypromellose, low-substituted hydroxypropyl cellulose, magnesium carbonate, methacrylic acid-ethyl acrylate copolymer (1:1), methacrylic acid-methyl methacrylate copolymer (1:1), methacrylic acid-methyl methacrylate copolymer (1:2), macrogol 8000, polysorbate 80, sucrose, sugar spheres, talc, titanium dioxide and triethyl citrate.</p><p><em>Capsule shell 30 mg:</em> Carrageenan, titanium dioxide, hypromellose, potassium chloride, purified water, indigotine and black iron oxide.</p><p><em>Capsule shell 60 mg:</em> Carrageenan, titanium dioxide, hypromellose, potassium chloride, purified water and indigotine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Instigar 30 mg Modified-release Hard Capsules are modified-release hard capsules with opaque blue cap and opaque gray body, printed with dark gray logo “TAP” on the cap and “30 mg” on the body containing white to off-white granules in aluminum-aluminum blisters.

Pack sizes: 14 and/or 28 Modified-release hard capsules. 

Not all pack sizes may be marketed.

Instigar 60 mg Modified-release Hard Capsules are modified-release hard capsules with opaque blue cap and body, printed with dark gray logo “TAP” on the cap and “60 mg” on the body containing white to off-white granules in aluminum-aluminum blisters.

Pack size: 28 Modified-release hard capsules. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />The Arab Pharmaceutical Manufacturing PSC<br />P.O. Box 42<br />Sult, Jordan<br />Tel: + (962-5) 3492200<br />Fax: + (962-5) 3492203</p><p><strong>Under license from</strong><br />Takeda Pharmaceuticals International AG, Switzerland &nbsp;<br />Thurgauerstrasse 130 CH-8152<br />Glattpark-Opfikon (Zurich),<br />Switzerland</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Center (NPC)<br />SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2023; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إنستيجار على المادة الفعالة ديكسلانسوبرازول، وهو مثبط لمخضة البروتون. تقلل مثبطات مضخة البروتون من كمية الحمض الذي تفرزه المعدة.</p><p dir="RTL">يستخدم إنستيجار في البالغين والمراهقين الذين تبلغ أعمارهم 12 عامًا فما فوق لما يلي:</p><ul dir="rtl"><li>علاج التهاب الارتجاع المريئي&nbsp;التقرحي (التهاب مع تلف بطانة المريء (قناة الطعام))</li><li>الحفاظ على التهاب&nbsp;الارتجاع المريئي&nbsp;التقرحي الذي &nbsp;تم علاجه والحفاظ على تخفيف حرقة المعدة</li><li>العلاج قصير الأمد لحرقة المعدة والحمض القلسي المرتبط بمرض الارتجاع المعدي-المريئي غير التقرحي المصحوب بأعراض. مرض الارتجاع المعدي-المريئي هو حالة تتسرب فيها أحماض المعدة إلى خارج المعدة وترتفع إلى المريء (ارتجاع الحمض).</li></ul><p dir="RTL">من خلال تقليل كمية حمض المعدة، يمكن لإنستيجار علاج تلف المريء وتخفيف الأعراض التي قد تحدث مع الحالات السابقة ومنعها من العودة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول إنستيجار:&nbsp;</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لديكسلانسوبرازول أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li></ul><p><strong>الاحتياطات والتحذيرات&nbsp;</strong><br />تحدث مع طبيبك قبل أو أثناء استخدام إنستيجار:</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل في الكبد. قد يضطر الطبيب إلى تعديل جرعتك.</li><li>إذا كنت تعاني من مشاكل في المعدة. قد يقوم طبيبك بإجراء فحص إضافي يُعرف بالتنظير الداخلي (حيث يتم إدخال كاميرا صغيرة جدًا في المريء لفحص داخل المعدة)، مما قد يساعد في استبعاد الأسباب الأكثر خطورة التي قد تسبب الأعراض لديك.</li><li>إذا كنت تأخذ مثبط لمضخة البروتون مثل إنستيجار، وخاصةً على مدى فترة تزيد عن سنة، فقد يزيد قليلا خطر الإصابة بكسر في الورك، الرسغ أو العمود الفقري. أخبر الطبيب إذا كنت تعاني من هشاشة العظام (انخفاض كثافة العظام) أو إذا أخبرك الطبيب أنك معرض لخطر الإصابة بهشاشة العظام (على سبيل المثال، إذا كنت تأخذ الستيرويدات القشرية).</li><li>إذا كنت تأخذ إنستيجار على أساس طويل الأمد (أطول من سنة واحدة). قد يطلب منك طبيبك أن يراك بانتظام للتحقق من مدى تحسنك. أخبر طبيبك إذا لاحظت أية أعراض جديدة أو إذا تفاقم أي من الأعراض لديك.</li><li>إذا كنت تتناول أدوية أخرى مثل ديجوكسين (لعلاج مشاكل القلب) أو مدرات البول (&rsquo;أقراص الماء&lsquo;). سيقوم طبيبك على الأرجح بمراقبة مستويات المغنيسيوم في دمك بانتظام.</li><li>إذا كانت مستويات فيتامين ب<sub>12</sub> منخفضة لديك أو لديك أحد عوامل خطر حدوث انخفاض في مستويات فيتامين ب<sub>12</sub> وكنت تتلقى علاجًا طويل الأمد باستخدام إنستيجار. كما هو الحال مع جميع عوامل تقليل الأحماض، قد يؤدي إنستيجار إلى تقليل امتصاص فيتامين ب<sub>12</sub>. &nbsp;</li><li>إذا سبق وأن حدث لك في أي وقت مضى رد فعل جلدي بعد العلاج بدواء مشابه لإنستيجار والذي يقلل من حمض المعدة.</li><li>إذا أصبت بطفح جلدي، وخاصةً في المناطق المعرضة للشمس، أخبر الطبيب بأسرع وقت ممكن، لأنك قد تحتاج إلى إيقاف العلاج مع إنستيجار. وتذكر أيضًا أن تذكر أي آثار مرضية أخرى مثل ألم المفاصل.</li><li>قد يحدث التهاب في الكلية عند تناول ديكسلانسوبرازول. قد تشمل العلامات والأعراض انخفاض حجم البول أو ظهور دم في البول و/أو تفاعلات فرط الحساسية مثل الحمى، الطفح، وتيبُّس المفصل. يجب أن تقوم بإبلاغ الطبيب المعالج بمثل هذه العلامات.</li><li>من الممكن أن يسبب ديكسلانسوبرازول ردود فعل جلدية نادرة ولكنها&nbsp; شديدة والتي قد تؤثر على أي جزء من الجسم (انظر أيضاً القسم 4). قد تحتاج ردود الفعل الجلدية الخطيرة هذه إلى العلاج في المستشفى وقد تكون مهددة للحياة؛ طفح جلدي الذي قد يحتوي على بثور، تقشر أو نزيف على أي جزء من الجلد (ويشمل ذلك الشفتين، العينين، الفم، الأنف، الأعضاء التناسلية، اليدين أو القدمين). وقد تصاب أيضاً بالحمى، القشعريرة، آلام الجسم، ضيق النفس، أو تضخم العقد اللمفية. توقف عن تناول إنستيجار وتحدث إلى طبيبك على الفور. قد تكون هذه الأعراض أول علامة على رد الفعل الجلدي الشديد.</li><li>إذا كان من المخطط لك أن تخضع لاختبار معين في الدم (اختبار كروموغرانين أ).</li></ul><p dir="RTL"><strong>الأطفال&nbsp;</strong><br />لا يعطى هذا الدواء للأطفال الذين تقل أعمارهم عن 12 عامًا.</p><p><strong>&nbsp;الأدوية الأخرى وإنستيجار&nbsp;</strong><br />أخبر طبيبك إذا كنت تأخذ، أخذت مؤخرًا، أو قد تأخذ أية أدوية أخرى. ذلك لأن ديكسلانسوبرازول قد يؤثر على طريقة عمل بعض الأدوية الأخرى. وكذلك، قد تؤثر بعض الأدوية على طريقة عمل ديكسلانسوبرازول.</p><p dir="RTL">تحقق مع طبيبك قبل تناول إنستيجار إذا كنت تتناول أيًّا من الأدوية التالية:</p><ul dir="rtl"><li>مثبطات بروتياز فيروس نقص المناعة البشري مثل أتازانافير ونيلفينافير (لعلاج فيروس نقص المناعة البشري)</li><li>كيتوكونازول، إيتراكونازول، ريفامبيسين (لعلاج العدوى)</li><li>إرلوتينيب (لعلاج السرطان)</li><li>ديجوكسين (لعلاج مشاكل القلب)</li><li>تاكروليموس (لمنع رفض العضو المزروع)</li><li>فلوفوكسامين (لعلاج الاكتئاب والأمراض النفسية الأخرى)</li><li>ورافارين (لمنع تجلط الدم)</li><li>مضادات الحموضة (لعلاج حرقة المعدة أو الحمض القلسي)</li><li>سوكرالفات (لعلاج القرحات)</li><li>نبتة سانت جونز (نبات هيوفاريقون) (لعلاج الاكتئاب الخفيف)</li><li>ميثوتركسيت (لعلاج السرطان)</li></ul><p dir="RTL"><strong>الحمل والرضاعة&nbsp;</strong><br />استشيري طبيبك أو الصيدلي إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp;</strong><br />تحدث أحيانا الآثار الجانبية مثل الدوخة، الدوار، التعب والاضطرابات البصرية لدى المرضى الذين يتناولون ديكسلانسوبرازول. إذا تعرضت لآثاراً جانبيةً مثل هذه، فيجب عليك أخذ الحيطة والحذر حيث أن قدرتك على الاستجابة قد تنخفض.</p><p>أنت وحدك تتحمل مسؤولية تحديد ما إذا كنت في حالة مناسبة لقيادة مركبة أو أداء مهام أخرى تتطلب زيادة في التركيز. أحد العوامل التي تقلل قدرتك على القيام بهذه الأشياء بأمان هو استخدامك للأدوية، وذلك بسبب آثارها أو الآثار غير المرغوب بها.</p><p>يمكن العثور على وصف لهذه الآثار في أقسام أخرى.</p><p>اقرأ جميع المعلومات الموجودة في هذه النشرة للحصول على الارشادات.</p><p>ناقش مع طبيبك إذا كنت غير متأكد حول أي شيء.</p><p><strong>يحتوي إنستيجار على السكروز&nbsp;</strong><br />يحتوي إنستيجار على السكروز. تحتوي كل كبسولة صلبة معدّلة الإطلاق من إنستيجار 30 ملغم و60 ملغم كبسولات صلبة معدّلة الإطلاق على 68 ملغم أو 76 ملغم سكروز؛ على التوالي. إذا أخبرك طبيبك بأن لديك عدم تحمل لبعض أنواع السكريات، فاتصل بطبيبك قبل تناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائماً هذا الدواء كما أخبرك طبيبك أو الصيدلي تماماً. تأكد من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">ابتلع الكبسولات كاملة مع كأس من الماء. يمكنك تناول الكبسولات مع أو بدون الطعام. إذا كنت تعاني من صعوبة في بلع كبسولات إنستيجار كاملة، يمكنك فتح الكبسولات ورش محتوياتها على ملعقة طعام من مهروس التفاح (مثل صلصة التفاح). تأكد من ابتلاع خليط التفاح على الفور. لا تمضغ الخليط. لا تحفظ الخليط لاستخدامه فيما بعد.</p><p dir="RTL"><strong>الجرعة الموصى بها للبالغين هي كما يلي:</strong></p><ul dir="rtl"><li>علاج التهاب الارتجاع المريئي التقرحي<strong>: </strong>تناول 60 ملغم مرة واحدة يوميًا لمدة 4 أسابيع. قد يصف طبيبك الدواء لـ 4 أسابيع إضافية.</li><li>الحفاظ على التهاب&nbsp;الارتجاع المريئي&nbsp;التقرحي الذي &nbsp;تم علاجه والحفاظ على تخفيف حرقة المعدة في المرضى الذين يحتاجون إلى كبت الحمض لفترات طويلة: تناول 30 ملغم مرة واحدة يوميًا لمدة تصل إلى 6 أشهر.</li><li>علاج حرقة المعدة والحمض القلسي المرتبط بمرض الارتجاع المعدي-المريئي غير التقرحي المصحوب بأعراض: تناول 30 ملغم مرة واحدة يوميًا لمدة تصل إلى 4 أسابيع.</li></ul><p dir="RTL"><strong>الجرعة الموصى بها للمراهقين البالغين من العمر 12 إلى 17 عامًا هي كالتالي:</strong></p><ul dir="rtl"><li>علاج التهاب الارتجاع المريئي التقرحي:<strong> </strong>تناول 60 ملغم مرة واحدة يوميًا لمدة 4 أسابيع. قد يصف طبيبك الدواء لـ 4 أسابيع إضافية.</li><li>الحفاظ على التهاب&nbsp;الارتجاع المريئي&nbsp;التقرحي الذي &nbsp;تم علاجه والحفاظ على تخفيف حرقة المعدة في المرضى الذين يحتاجون إلى كبت الحمض لفترات طويلة: تناول 30 ملغم مرة واحدة يوميًا. سيحدد طبيبك إجمالي وقت العلاج.</li><li>علاج حرقة المعدة والحمض القلسي المرتبط بمرض الارتجاع المعدي-المريئي غير التقرحي المصحوب بأعراض: تناول 30 ملغم مرة واحدة يوميًا لمدة تصل إلى 4 أسابيع.</li></ul><p dir="RTL"><strong>كبار السن والمرضى المصابون بمشاكل في الكبد: </strong>قد يصف طبيبك جرعة أقل.</p><p dir="RTL">سوف ينصحك طبيبك بالمدة الزمنية لتناول دواء إنستيجار.</p><p dir="RTL">إذا لزم الأمر، قد يخبرك طبيبك بأخذ جرعة مختلفة.</p><p dir="RTL"><strong>إذا تناولت إنستيجار أكثر من اللازم&nbsp;</strong><br />إذا تناولت عدة كبسولات عن طريق الخطأ (جرعة زائدة)، أو إذا تناول شخص آخر جرعات متعددة من دوائك في نفس الوقت، تحدث إلى الطبيب على الفور.</p><p>تم الإبلاغ عن الأعراض التالية في المرضى الذين تناولوا جرعات كبيرة من ديكسلانسوبرازول:</p><ul dir="rtl"><li>ارتفاع ضغط الدم، هبات ساخنة، تكدمات، ألم الحلق وفقدان الوزن.</li></ul><p><strong>إذا نسيت تناول إنستيجار&nbsp;</strong><br />إذا نسيت تناول جرعة، قم بتناولها فور تذكرها إلا إذا كان موعد الجرعة التالية قد اقترب. إذا حدث ذلك، تخط الجرعة المنسية وتابع بجرعتك التالية كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>إذا توقفت عن تناول إنستيجار&nbsp;</strong><br />لا تتوقف عن تناول العلاج مبكرًا لمجرد شعورك أنك تحسنت. فقد لا يكون تم علاج حالتك تماماً وقد تعود حالتك إذا لم تكمل الدورة العلاجية. تحدث إلى طبيبك قبل إيقاف هذا العلاج.</p><p>إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، إسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">في الدراسات السريرية، كانت الآثار الجانبية المرتبطة بالعلاج باستخدام ديكسلانسوبرازول خفيفة إلى متوسطة.</p><p dir="RTL"><strong>إذا أصبت بأي من الآثار الجانبية التالية، توقف عن تناول هذه الكبسولات وأخبر الطبيب فورًا، أو اتصل بقسم الطوارئ في أقرب مستشفى لك:</strong></p><ul dir="rtl"><li>فرط الحساسية أو تفاعلات حساسية خطيرة (غير معروفة التكرار) مثل الطفح الجلدي، تورم الوجه، ضيق الحلق، صعوبة في التنفس</li><li>صدمة تأقية أو تفاعل تحسسي خطير، شديد ومفاجئ (غير معروفة التكرار) مع حدوث أعراض مثل ضيق النفس، تشوش، شحوب اللون تهيج جلدي خطير، ضيق الحلق، ضعف، التلهث طلبًا للهواء وفقدان الوعي.</li></ul><p dir="RTL"><strong>الآثار الجانبية الأكثر شيوعًا (شائعة - قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص) التي تم الابلاغ عنها هي</strong>:</p><ul dir="rtl"><li>الإسهال، ألم البطن، الصداع، الغثيان، عدم ارتياح في البطن، الغازات (انتفاخ البطن)، الإمساك والأورام الحميدة في المعدة.</li></ul><p dir="RTL"><strong><em>عانى بعض المرضى من الآثار الجانبية الأخرى التالية مع</em></strong> <strong><em>ديكسلانسوبرازول</em></strong><strong><em>:&nbsp;</em></strong><br /><strong>غير الشائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>صعوبة في النوم</li><li>الاكتئاب</li><li>الدوخة</li><li>تغير حاسة الذوق</li><li>ارتفاع ضغط الدم</li><li>هبات ساخنة</li><li>السعال</li><li>القيء</li><li>جفاف الفم</li><li>اضطراب في اختبارات وظائف الكبد</li><li>الشرى</li><li>الحكة</li><li>الطفح</li><li>الشعور بالضعف</li><li>تغيرات في الشهية</li><li>كسر في الورك، الرسغ أو العمود الفقري</li></ul><p><strong>نادرة (تؤثر فيما يصل إلى شخص واحد من كل 1000 شخص)</strong></p><ul dir="rtl"><li>هلوسات تتضمن سماع أصوات</li><li>تشنجات</li><li>وخز أو تنميل</li><li>اضطرابات بصرية</li><li>الشعور بدوار أو &quot;دوخة&quot;</li><li>عداوى فطرية</li></ul><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير التكرار من البيانات المتاحة):</strong></p><ul dir="rtl"><li>انخفاض عدد خلايا الدم الحمراء. قد يسبب ذلك الشحوب، الضعف، عدم تحمل ممارسة النشاط البدني، الدوار، التعب والتشوش</li><li>التكدم أو النزيف بسبب انخفاض عدد الصفائح الدموية بشكل غير طبيعي لسبب غير معروف</li><li>ردود فعل جلدية شديدة (متلازمة ستيفنز جونسون)، تقشّر الأنسجة المتموّتة&nbsp;البَشْروية&nbsp;التسممي، التفاعل الدوائي مع اليُوزينِيَّات والأعراض الجهازية، الحُمامَى&nbsp;العَديدَةُ&nbsp;الأَشْكالِ، وذِئْبَةٌ حُمَامِيَّةٌ جِلْدِيَّة تحت الحادة. قد تعاني أيضاً من ألم المفصل أو أعراض مشابهة للإِنْفلوَنْزَا مثل الحمى، تورم الغدد (في منطقة الإبط على سبيل المثال) وقد تُظهر فحوصات الدم تغيرات في بعض خلايا الدم البيضاء أو انزيمات الكبد.</li><li>تغيُّم الرؤية</li><li>الصمم</li><li>التهاب الكبد بسبب الأدوية (المصحوب بأعراض مثل فقدان الشهية، الصداع، الغثيان، التعب، الحمى، اليرقان، براز فاتح أو بلون الطين، بول داكن)</li><li>الطفح، قد يكون مع ألم في المفاصل</li><li>إذا كنت تأخذ ديكسلانسوبرازول لأكثر من ثلاثة أشهر، من الممكن أن تنخفض مستويات المغنيسيوم في الدم. ويمكن ملاحظة انخفاض مستويات المغنيسيوم على شكل تعب، تقلصات العضلات لاإرادياً، التوهان، التشنجات، الدوخة، زيادة معدل ضربات القلب. إذا أصبت بأي من هذه الأعراض، فيرجى إخبار الطبيب فورًا. يمكن أن يؤدي انخفاض مستويات المغنيسيوم إلى انخفاض في مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر الطبيب إجراء فحوص دم عادية لمراقبة مستويات المغنيسيوم.</li><li>انخفاض مستويات الصوديوم في الدم. الأعراض الشائعة تشمل الغثيان والقيء، الصداع، النعاس والتعب، التشوش، ضعف أو تشنج العضلات، التهيج، النوبات، الغيبوبة.</li><li>مشاكل في الكلية</li><li>هلوسات بصرية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30˚ مئوية. &nbsp;</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. &nbsp;يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ديكسلانسوبرازول.</p><p dir="RTL">تحتوي كل كبسولة صلبة معدّلة الإطلاق من إنستيجار 30 ملغم و60 ملغم كبسولات صلبة معدّلة الإطلاق على 30 ملغم أو 60 ملغم ديكسلانسوبرازول؛ على التوالي.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>محتو</em><em>ى</em><em> الكبسولة:<strong> </strong></em>سيليكا غروية لامائية، هيدروكسي بروبيل السيلليلوز، هيبروميللوز، هيدروكسي بروبيل السيلليلوز منخفض الاستبدال، كربونات المغنيسيوم، بوليمر مشترك لحمض الميثاكريليك-إيثيل أكريلات (1:1)، بوليمر مشترك لحمض الميثاكريليك-ميثيل ميثاكريلات (1:1)، بوليمر مشترك لحمض الميثاكريليك-ميثيل ميثاكريلات (2:1)، ماكروجول 8000، متعدد السوربات 80، سكروز، كرات السكر، تالك، ثاني أكسيد التيتانيوم وسيترات ثلاثي الإيثيل.</p><p dir="RTL"><em>قشرة الكبسولة 30 ملغم: </em>كاراجينان، ثاني أكسيد التيتانيوم، هيبروميللوز، كلوريد البوتاسيوم، ماء منقى، إنديجوتين وأكسيد الحديد الأسود.</p><p dir="RTL"><em>قشرة الكبسولة 60 ملغم: </em>كاراجينان، ثاني أكسيد التيتانيوم، هيبروميللوز، كلوريد البوتاسيوم، ماء منقى وإنديجوتين.<strong><em> </em></strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إنستيجار 30 ملغم كبسولات صلبة معدّلة الإطلاق هي كبسولات صلبة معدّلة الإطلاق بغطاء أزرق معتم وجسم رمادي معتم، مطبوع عليها باللون الرمادي الغامق شعار &quot;TAP&quot; على الغطاء و&quot;30mg&quot; على الجسم وتحتوي على حبيبات لونها أبيض مائل إلى الأبيض المصفر في أشرطة من الألومنيوم-الألومنيوم.</p><p dir="RTL">أحجام العبوات: 14 و/أو 28 كبسولة صلبة معدّلة الإطلاق.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">إنستيجار 60 ملغم كبسولات صلبة معدّلة الإطلاق هي كبسولات صلبة معدّلة الإطلاق بغطاء وجسم أزرق معتم، مطبوع عليها باللون الرمادي الغامق شعار &quot;TAP&quot; على الغطاء و&quot;60mg&quot; على الجسم وتحتوي على حبيبات لونها أبيض مائل إلى الأبيض المصفر في أشرطة من الألومنيوم-الألومنيوم.</p><p dir="RTL">حجم العبوة: 28 كبسولة صلبة معدّلة الإطلاق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية&nbsp;<br />طريق الخرج&nbsp;<br />صندوق بريد 106229&nbsp;&nbsp;<br />الرياض 11666، المملكة العربية السعودية&nbsp;<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +&nbsp;<br />فاكس: 2078170 (11-966) +&nbsp;<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة&nbsp;</strong><br />الشركة العربية لصناعة الأدوية المساهمة الخاصة&nbsp;<br />صندوق بريد 42&nbsp;<br />السلط، الأردن&nbsp;<br />هاتف: 3492200 (5-962) +&nbsp;<br />فاكس: 3492203 (5-962) +</p><p dir="RTL"><strong>بترخيص من&nbsp;</strong><br />شركة تاكيدا الدوائية الدولية المحدودة، سويسرا&nbsp;<br />شارع ثورجور 130 CH-8152&nbsp;<br />جلاتبارك-أوبفيكون (زيورخ)،&nbsp;<br />سويسرا</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية<strong> </strong></li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي&nbsp;<br />مركز الاتصال الموحد: 19999&nbsp;<br />البريد الإلكتروني: npc.drug@sfda.gov.san<br />الموقع الإلكتروني: https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 12/2023؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Instigar 30 mg Modified-release Hard Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each modified-release hard capsule contains 30 mg dexlansoprazole.

Excipient with known effect: Sucrose.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Modified-release hard capsules.

Modified-release hard capsules with opaque blue cap and opaque gray body, printed with dark gray logo “TAP” on the cap and “30 mg” on the body containing white to off-white granules. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Instigar is indicated in adults and in adolescents aged 12 to 17 years for the following:</p><ul><li>Treatment of erosive reflux oesophagitis</li><li>Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn</li><li>Short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong></p><p><strong>Treatment of erosive reflux oesophagitis</strong></p><p><em>Adults and adolescents aged 12 to 17 years </em>- The recommended dose is 60 mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks.</p><p><strong>Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn</strong></p><p><em>Adults </em>- The recommended dose is 30 mg once daily for up to 6 months in patients where prolonged acid suppression is needed.</p><p><em>Adolescents aged 12 to 17 years </em>- The recommended dose is 30 mg once daily. Current evidence does not support a specific treatment period time. A decision should be taken by the clinician on a case by case basis.</p><p><strong>Symptomatic non-erosive gastro-oesophageal reflux disease (GORD)</strong></p><p><em>Adults and adolescents aged 12 to 17 years </em>- The recommended dose is 30 mg once daily for up to 4 weeks.</p><p><strong><em>Special populations</em></strong></p><p><strong>Elderly</strong></p><p>Due to reduced clearance of dexlansoprazole in the elderly an adjustment of dose may be necessary based on individual requirements. A daily dose of 60 mg should not be exceeded in the elderly unless there are compelling clinical indications (see section 5.2).</p><p><strong>Renal impairment</strong></p><p>No dosage adjustment is necessary for patients with renal impairment (see section 5.2).</p><p><strong>Hepatic impairment</strong></p><p>No dosage adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment should be kept under regular supervision and a maximum daily dose of 30 mg should be considered. No studies have been conducted in patients with severe hepatic impairment (see sections 4.4 and 5.2), the use of dexlansoprazole is not recommended for these patients.</p><p><strong>Paediatric population</strong></p><p><u>Adolescents aged 12 to 17 years</u></p><p><em>Treatment of erosive reflux oesophagitis</em></p><p>The posology of Instigar in adolescents aged 12 to 17 years is the same as in adults.</p><p><em>Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn</em></p><p>The dose of Instigar in adolescents aged 12 to 17 years is the same as in adults.</p><p><em>Symptomatic non-erosive gastro-oesophageal reflux disease (GORD)</em></p><p>The posology of Instigar in adolescents aged 12 to 17 years is the same as in adults.</p><p><u>Children under 12 years of age</u></p><p>The safety and efficacy of dexlansoprazole in children under 12 years of age have not been established. No data are available. The use of Instigar is not recommended in children under 12 years of age as clinical data are limited (see section 5.2) and juvenile animal studies have findings of currently unknown human relevance (see section 5.3). Treatment of small children below one year of age should be avoided as available data have not shown beneficial effects in the treatment of gastro-oesophageal reflux disease.</p><p><strong><em>Method of administration</em></strong></p><p>Oral use.</p><p>Capsules should be swallowed whole with liquid. They can be taken with or without food (see section 5.2).</p><p>Capsules may also be opened, and granules mixed with one tablespoon apple sauce for administration. After preparing the mixture, the medicinal product should be administered immediately.</p><p>Granules should not be chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastric malignancy</u></p><p>The possibility of malignant gastric tumour should be excluded when using Instigar because dexlansoprazole can mask the symptoms and delay the diagnosis.</p><p><u>HIV protease inhibitors</u></p><p>Co-administration of dexlansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir or nelfinavir, due to significant reduction in their bioavailability (see section 4.5).</p><p><u>Hepatic Impairment</u></p><p>Dexlansoprazole should be used with caution in patients with moderate hepatic dysfunction. Dexlansoprazole is not recommended for patients with severe hepatic impairment (see sections 4.2 and 5.2).</p><p><u>Gastrointestinal infections caused by bacteria</u></p><p>Decreased gastric acidity due to any means, including proton pump inhibitors (PPIs) such as dexlansoprazole, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella</em>, <em>Campylobacter </em>and <em>Clostridium difficile</em>.</p><p><u>Long term treatment</u></p><p>Because of limited safety data for patients on treatment for longer than 1 year, regular review of the treatment and a thorough risk/benefit assessment should regularly be performed in these patients.</p><p><u>Hypomagnesaemia</u></p><p>Severe hypomagnesaemia has been rarely reported in patients treated with PPIs like dexlansoprazole for at least three months, in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, delirium, convulsions, dizziness and ventricular arrhythmia can occur, but they may begin insidiously and be overlooked. Hypomagnesaemia may lead to hypocalcaemia and/or hypokalaemia (see section 4.8). In most affected patients, hypomagnesaemia (and hypomagnesaemia associated hypocalcaemia and/or hypokalaemia) improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p><u>Influence on Vitamin B<sub>12</sub> Absorption</u></p><p>Dexlansoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B-12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B-12 absorption on long-term therapy or if respective clinical symptoms are observed.</p><p><u>Gastrointestinal disorders</u></p><p>Very rarely cases of colitis have been reported in patients taking lansoprazole. Similar effects could be expected with dexlansoprazole. Therefore, in the case of severe and/or persistent diarrhoea, discontinuation of therapy should be considered.</p><p><u>Bone fractures</u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in the presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><u>Methotrexate</u></p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high dose methotrexate administration a temporary withdrawal of dexlansoprazole may need to be considered.</p><p><u>Severe Cutaneous Adverse Reactions</u></p><p>Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and erythema multiforme have been reported in association with the use of PPIs (see section 4.8). Discontinue dexlansoprazole at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Instigar. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p><u>Renal impairment </u></p><p>Acute tubulointerstitial nephritis (TIN) has been observed in patients taking dexlansoprazole and may occur at any point during dexlansoprazole therapy (see section 4.8). Acute tubulointerstitial nephritis can progress to renal failure.</p><p>Dexlansoprazole should be discontinued in case of suspected TIN, and appropriate treatment should be promptly initiated.</p><p><u>Interference with laboratory tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Instigar treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p><strong>Instigar contains sucrose<u> </u></strong></p><p>Instigar contains sucrose. Each modified-release hard capsule of Instigar 30 mg Modified-release Hard Capsules contains 68 mg sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p><strong>Effects of other medicinal products on dexlansoprazole</strong></p><p>CYP2C19 and CYP3A4 have been shown to be involved in the metabolism of dexlansoprazole.</p><p><u>Medicinal products which inhibit CYP2C19</u></p><p>Inhibitors of CYP2C19 (such as fluvoxamine) would likely increase the systemic exposure of dexlansoprazole.</p><p><u>Medicinal products which induce CYP2C19 and CYP3A4</u></p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin, and St John&rsquo;s wort (<em>Hypericum perforatum</em>) may reduce the plasma concentrations of dexlansoprazole.</p><p><u>Others</u></p><p><em>Sucralfate/Antacids</em></p><p>Sucralfate/Antacids may decrease the bioavailability of dexlansoprazole. Therefore dexlansoprazole should be taken at least 1 hour after taking these drugs.</p><p><strong>Effects of dexlansoprazole on other medicinal products</strong></p><p><u>Medicinal products with pH dependent absorption</u></p><p>Dexlansoprazole may interfere with the absorption of medicinal products where gastric pH is critical to bioavailability.</p><p><em>HIV protease inhibitors</em></p><p>Co-administration of dexlansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir or nelfinavir; due to significant reduction in their bioavailability (see section 4.4).</p><p><em>Ketoconazole, itraconazole and erlotinib</em></p><p>The absorption of ketoconazole, itraconazole and erlotinib from the gastrointestinal tract is enhanced by the presence of gastric acid. Administration of dexlansoprazole may result in sub-therapeutic concentrations of ketoconazole, itraconazole and erlotinib, and the combination should be avoided.</p><p><em>Digoxin</em></p><p>Co-administration of dexlansoprazole and digoxin may lead to increased digoxin plasma levels. The plasma levels of digoxin should therefore be monitored and the dose of digoxin adjusted if necessary when initiating and ending dexlansoprazole treatment.</p><p><u>Medicinal products metabolised by P450 enzymes</u></p><p><em>In vitro </em>studies have shown that dexlansoprazole is not likely to inhibit CYP isoforms 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 or 3A4. As such, no clinically relevant interactions with medicinal products metabolised by these CYP enzymes would be expected. Furthermore, <em>in vivo </em>studies showed that dexlansoprazole did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate) or theophylline (CYP1A2 substrate). The subjects&rsquo; CYP1A2 genotypes in the drug-drug interaction study with theophylline were not determined. Although <em>in vitro </em>studies demonstrated that dexlansoprazole has the potential to inhibit CYP2C19, an <em>in vivo </em>drug-drug interaction study in mainly CYP2C19 extensive and intermediate metabolisers has shown that dexlansoprazole does not affect the pharmacokinetics of diazepam (CYP2C19 substrate).</p><p><em>Tacrolimus</em></p><p>Co-administration of dexlansoprazole may increase the plasma concentrations of tacrolimus (a CYP3A and P-glycoprotein [P-gp] substrate), especially in transplant patients who are intermediate or poor metabolisers of CYP2C19. Monitoring of tacrolimus plasma concentrations is advised when concomitant treatment with dexlansoprazole is initiated or ended.</p><p><em>Warfarin</em></p><p>In a study, co-administration of dexlansoprazole and warfarin did not result in any significant differences in the pharmacokinetics of warfarin or International Normalised Ratio (INR) compared to administration of warfarin with placebo. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time, especially when initiating or ending concomitant treatment.</p><p><em>Clopidogrel</em></p><p>A study has shown that concomitant administration of dexlansoprazole (60 mg once daily) and clopidogrel 75 mg to healthy volunteers resulted in a reduction in the exposure to the active metabolite of clopidogrel (approximately 9% decrease in AUC and 27% decrease in Cmax). Co-administration of dexlansoprazole had no clinically meaningful effect on pharmacodynamics of clopidogrel. No dose adjustment of clopidogrel is necessary when administered with an approved dose of dexlansoprazole.</p><p><u>Methotrexate</u></p><p>Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate possibly leading to methotrexate toxicities. Therefore, in settings where high-dose methotrexate is used a temporary withdrawal of dexlansoprazole may need to be considered. However, no formal drug interaction studies of high-dose methotrexate with PPIs have been conducted.</p><p><u>Medicinal products transported by P-glycoprotein</u></p><p>Lansoprazole has been observed to inhibit the transport protein, P-gp <em>in vitro. </em>Similar effects could be expected with dexlansoprazole. The clinical relevance of this is unknown.</p><p><u>Others</u></p><p>No clinically significant interactions of dexlansoprazole with nonsteroidal anti-inflammatory drugs have been demonstrated, although no formal interactions studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no or limited amount of data from the use of dexlansoprazole in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure<strong>, </strong>it is preferable to avoid the use of Instigar during pregnancy.</p><p><strong>Breastfeeding</strong></p><p>It is not known whether dexlansoprazole is excreted in human breast milk. Animal studies have shown excretion of lansoprazole in milk.</p><p>A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><strong>Fertility</strong></p><p>There was no evidence of impaired fertility following the administration of lansoprazole in animal studies (see section 5.3). Similar results could be expected with dexlansoprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse drug reactions such as dizziness, vertigo, visual disturbances and somnolence may occur (see section 4.8). Under these conditions the ability to react may be decreased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p><u>Adults</u></p><p>dexlansoprazole at doses of 30, 60, or 90 mg has been evaluated for safety in clinical studies in patients treated for up to 1 year. In these clinical studies, adverse reactions associated with treatment with dexlansoprazole were mostly mild or moderate, with an overall incidence similar to placebo and lansoprazole. The most commonly reported adverse reactions were diarrhoea, abdominal pain, headache, nausea, abdominal discomfort, flatulence and constipation. The incidence of these adverse reactions was not affected by gender, age, or race.</p><p><strong>Tabulated list of adverse reactions</strong></p><p>Adverse reactions reported for dexlansoprazole (30 mg, 60 mg or 90 mg) in clinical studies and post-marketing experience are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). For all adverse reactions reported from post marketing experience, it is not possible to apply any Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency. &nbsp;Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td><p>Blood and lymphatic System disorders</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Autoimmune haemolytic anaemia<sup>1,2</sup></p><p>Idiopathic thrombocytopenic purpura<sup>2</sup></p><p>&nbsp;</p></td></tr><tr><td><p>Immune system disorders</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic reaction<sup>2</sup></p><p>Hypersensitivity<sup>1,2</sup></p><p>Anaphylactic shock<sup>2</sup></p></td></tr><tr><td><p>Metabolism and nutrition disorders</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hyponatremia<sup>2</sup></p><p>Hypomagnesaemia<sup>2</sup></p><p>Hypocalcaemia<sup>2,3</sup></p><p>Hypokalaemia<sup>2,3</sup></p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>&nbsp;</p></td><td><p>Insomnia</p><p>Depression</p></td><td><p>Auditory</p><p>hallucinations</p></td><td><p>Visual hallucinations</p><p>&nbsp;</p></td></tr><tr><td><p>Nervous system disorders</p><p>&nbsp;</p></td><td><p>Headache</p></td><td><p>Dizziness</p><p>Altered taste</p></td><td><p>Convulsion</p><p>Paraesthesia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Visual disturbance</p></td><td><p>Blurred vision<sup>2</sup></p><p>&nbsp;</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Vertigo</p></td><td><p>Deafness<sup>2</sup></p><p>&nbsp;</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>&nbsp;</p></td><td><p>Hypertension</p><p>Hot flushes</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Cough</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Diarrhoea<sup>1</sup></p><p>Abdominal pain<sup>1</sup></p><p>Nausea</p><p>Abdominal</p><p>discomfort</p><p>Flatulence</p><p>Constipation</p><p>Fundic gland polyps (benign)</p></td><td><p>Vomiting</p><p>Dry mouth</p><p>&nbsp;</p></td><td><p>Candidiasis</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>&nbsp;</p></td><td><p>Liver function test abnormal</p></td><td><p>&nbsp;</p></td><td><p>Hepatitis drug-induced<sup>2</sup></p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>Urticaria</p><p>Pruritus</p><p>Rash</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p><p>Stevens-Johnson syndrome<sup>2</sup></p><p>Toxic epidermal necrolysis<sup>2</sup></p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>2</sup></p><p>Erythema multiforme</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Tubulointerstitial nephritis<sup>2</sup> (with possible progression to renal failure)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td><td><p>Asthenia</p><p>Appetite changes</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup> see section &lsquo;Description of selected adverse reactions&rsquo;</p><p><sup>2</sup> adverse reactions that have been observed during post approval marketing events of dexlansoprazole (as these</p><p>reactions are reported voluntarily from a population of uncertain size, frequency cannot be estimated from the available data)</p><p><sup>3</sup> Hypocalcaemia and/or hypokalaemia may be related to the occurrence of hypomagnesaemia (see section&nbsp;4.4<em>)</em></p><p><strong>Description of selected adverse reactions</strong></p><p><em>Diarrhoea and abdominal pain</em></p><p>In the Phase 3 clinical studies, the most commonly reported adverse reaction was diarrhoea (excluding infective diarrhoea), the majority of which were non serious. Overall, few subjects (2.4%) prematurely discontinued due to an adverse reaction while receiving dexlansoprazole therapy. The most common (&ge; 0.5%) adverse reactions leading to premature discontinuation were diarrhoea, gastrointestinal and abdominal pains. Initial onset of diarrhoea and abdominal pain was independent of the duration of exposure, and the majority of these events were mild to moderate in severity. There were no apparent dose-related trends observed across dexlansoprazole doses for the incidence of these events.</p><p><em>Hypersensitivity</em></p><p>There have been post-marketing cases reporting serious hypersensitivity reactions. Hypersensitivity reactions were more frequently reported in females (74%). The majority of the serious cases were managed with steroids and/or antihistamines and withdrawal of the medicinal product. Severe reactions of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and erythema multiforme were reported in patients.</p><p><em>Haemolytic anaemia</em></p><p>There have been few serious post-marketing reports of haemolytic anaemia after approximately four to seven months on dexlansoprazole 60 mg therapy.</p><p><u>Paediatric population</u></p><p>The safety profile for adolescents aged 12 to 17 years is similar to adults. In clinical studies of 166 adolescent patients, the only adverse reaction that occurred in more than one patient was abdominal pain. Additional adverse reactions, which occurred in one patient each, included diarrhoea, urticaria, dry mouth and headache.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Center (NPC)</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of overdose of dexlansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instruction for treatment cannot be given.</p><p>There have been no reports of significant overdose of dexlansoprazole. Multiple doses of dexlansoprazole 120 mg and a single dose of dexlansoprazole 300 mg did not result in death or other severe adverse events. Serious adverse reactions of hypertension have been reported in association with twice daily doses of dexlansoprazole 60 mg. Non-serious adverse reactions observed with twice daily doses of dexlansoprazole 60 mg include hot flushes, contusion, oropharyngeal pain, and weight loss.</p><p>In the case of suspected overdose the patient should be monitored. Dexlansoprazole is not significantly eliminated by haemodialysis. If necessary, gastric emptying, charcoal and symptomatic therapy is recommended.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC06</p><p><strong>Mechanism of action</strong></p><p>Dexlansoprazole is the R-enantiomer of lansoprazole. It is a gastric PPI. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Dexlansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of H+/K+ATPase causing inhibition of the enzyme activity.</p><p><strong>Pharmacodynamic effects</strong></p><p><em>Antisecretory activity</em></p><p>The antisecretory activity of dexlansoprazole has been studied in healthy subjects taking dexlansoprazole 60 mg or lansoprazole 30 mg once daily for five days. The average intragastric pH was 4.55 for dexlansoprazole and 4.13 for lansoprazole. The average percentage of time throughout the day in which the intragastric pH is maintained above 4 was 71% (17 hours) with dexlansoprazole and 60% (14 hours) with lansoprazole.</p><p><em>Serum gastrin effect</em></p><p>The effect of dexlansoprazole on serum gastrin concentrations was evaluated in patients in clinical trials up to 12 months. The mean fasting gastrin concentrations increased from baseline during treatment with dexlansoprazole 30 mg and 60 mg doses. In patients treated for more than 6 months, mean serum gastrin levels increased during approximately the first 3 months of treatment and were stable for the remainder of treatment. Mean serum gastrin levels returned to pre-treatment levels within one month of discontinuation of treatment.</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also, CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p><em>Enterochromaffin-Like Cell (ECL) Effects</em></p><p>There were no reports of ECL cell hyperplasia in gastric biopsy specimens obtained from patients treated with dexlansoprazole 30 mg, 60 mg or 90 mg for up to 12 months.</p><p><em>Effect on Cardiac Repolarisation</em></p><p>A study was conducted to assess the potential of dexlansoprazole to prolong the QT/QTc interval in healthy adult subjects. dexlansoprazole doses of 90 mg or 300 mg did not delay cardiac repolarisation compared to placebo. The positive control (moxifloxacin) produced statistically significantly greater mean maximum and time-averaged QT/QTc intervals compared to placebo.</p><p><strong>Clinical efficacy and safety</strong></p><p><em>Treatment of erosive reflux oesophagitis</em></p><p>Two multi-centre, double-blind, active-controlled, randomised, 8-week studies were conducted in patients with endoscopically confirmed erosive reflux oesophagitis. Severity of the disease was classified based on the Los Angeles Classification Grading System (Grades A-D). Patients were randomised to one of the following three treatment groups: dexlansoprazole 60 mg daily, dexlansoprazole 90 mg daily or lansoprazole 30 mg daily. A total of 4092 patients were enrolled and ranged in age from 18 to 90 years (median age 48 years) with 54% male. Based on the Los Angeles Classification, 71% of patients had Grades A and B erosive reflux oesophagitis (mild) and 29% of patients had Grades C and D erosive reflux oesophagitis (moderate to severe) before treatment.</p><p>By the life-table method of analysis dexlansoprazole 60 mg healed 92.3% to 93.1% of patients versus 86.1% to 91.5% for lansoprazole 30 mg after 8 weeks of treatment (primary). Non-inferiority was demonstrated in both studies. Statistical superiority was not established using log-rank tests.</p><p>After 4 weeks of treatment (secondary), the healing rates by the life-table method were 77.0% to 80.1% versus 76.5% to 77.0% for lansoprazole 30 mg.</p><p>The life-table healing rates at Week 8 for patients with moderate to severe erosive reflux oesophagitis (secondary) were 88.9% and 74.5% for dexlansoprazole 60 mg and lansoprazole 30 mg, respectively, in the first study. The difference was statistically significant (p=0.011). In the second study, the Week 8 life-table healing rates were 87.6% and 87.7% for dexlansoprazole 60 mg and lansoprazole 30 mg, respectively, and were not statistically significantly different.</p><p>Dexlansoprazole 90 mg was studied and did not provide additional clinical benefit over dexlansoprazole 60 mg.</p><p><em>Maintenance of healed erosive </em><em>reflux oesophagitis</em></p><p>A multi-centre, double-blind, placebo-controlled, randomised study was conducted in patients who successfully completed an erosive reflux oesophagitis study and showed endoscopically confirmed healed erosive reflux oesophagitis. Maintenance of healing and symptom relief over a six-month period were evaluated with dexlansoprazole 30 mg or 60 mg once daily compared to placebo. A total of 445 patients were enrolled and ranged in age from 18 to 85 years (median age 49 years), with 52% female.</p><p>By the life-table method, dexlansoprazole 30 mg and 60 mg demonstrated statistically significantly higher rates of maintenance of healed erosive reflux oesophagitis (74.9% and 82.5%, respectively) than placebo (27.2%) at Month 6 (p&lt;0.00001).</p><p>For patients with more severe grades of erosive reflux oesophagitis (Grades C or D) before healing, dexlansoprazole 30 mg and 60 mg also achieved statistically significantly higher 6-month maintenance rates than placebo by the life-table method.</p><p>Dexlansoprazole 30 mg and 60 mg achieved statistically significantly (p&lt;0.00001) greater percentages of heartburn relief during the study treatment period. The median percentages of 24-hour heartburn-free days were 96.1%, 90.9% and 28.6% for dexlansoprazole 30 mg, 60 mg and placebo, respectively. The median percentages of nights without heartburn were 98.9%, 96.2% and 71.7% for dexlansoprazole 30 mg, 60 mg and placebo, respectively.</p><p>In a second study (N=451) of dexlansoprazole 60 mg and 90 mg versus placebo, dexlansoprazole 60 mg showed similar results to the first study in the maintenance of healed erosive reflux oesophagitis and heartburn relief. dexlansoprazole 90 mg did not provide additional clinical benefit over dexlansoprazole 60 mg.</p><p><em>Symptomatic non-erosive GORD</em></p><p>A multi-centre, double-blind, placebo-controlled, randomised, 4-week study was conducted in patients with a diagnosis of symptomatic GORD made primarily by presentation of symptoms. These patients who identified heartburn as their primary symptom, had a history of heartburn for 6 months or longer, had heartburn on at least 4 of 7 days immediately prior to randomisation and had no esophageal erosions as confirmed by endoscopy. However, patients with symptoms which were not acid-related may not have been excluded using these inclusion criteria. Patients were randomised to one of the following treatment groups: dexlansoprazole 30 mg daily, 60 mg daily, or placebo. A total of 947 patients were enrolled and ranged in age from 18 to 86 years (median age 48 years) with 71% female.</p><p>Dexlansoprazole 30 mg provided statistically significantly greater percent of days with heartburn-free 24-hour periods and percent of nights without heartburn (respectively 54.9% and 80.8%) over placebo (respectively 18.5% and 51.7%) as assessed by daily diary over 4 weeks. A higher percentage of patients on dexlansoprazole 30 mg had heartburn-free 24-hour periods compared to placebo through 4 weeks of treatment. dexlansoprazole 60 mg was studied and provided no additional clinical benefit over dexlansoprazole 30 mg.</p><p>A second multi-centre, double blind, placebo-controlled, randomised, 4-week study was conducted in patients with a history of nocturnal heartburn and GORD associated sleep disturbances on at least 3 of 7 nights immediately prior to randomisation. Patients were randomised to receive dexlansoprazole 30 mg or placebo daily. A total of 305 patients were enrolled and ranged in age from 18 to 66 years (median age 45 years) with 63.9% female. dexlansoprazole 30 mg provided statistically significantly greater percent of nights without heartburn (73.1%) over placebo (35.7%) as assessed by daily diary over 4 weeks.</p><p>A third multi-centre, single blind study enrolled 178 patients with a history of symptomatic GORD. Patients whose symptoms were well-controlled during a run-in period while taking a PPI other than dexlansoprazole twice a day subsequently received blinded dexlansoprazole 30 mg (morning) and placebo (evening) for 6 weeks. Well-controlled was defined as having a weekly average of &le;1 episode of heartburn during the last 4 weeks of both the 6 week run-in and treatment periods. A total of 142 patients were included in the analysis. Ages ranged from 22 to 90 years (median age 53 years) with 56% female. After switching from twice daily PPI therapy to once daily dexlansoprazole 30 mg, 88% of patients&rsquo; heartburn remained well-controlled.</p><p><strong>Paediatric population</strong></p><p><em>Treatment of erosive reflux oesophagitis, maintenance of healed erosive reflux oesophagitis and relief of heartburn</em></p><p>In a multi-centre, 24 week study, 62 adolescents with a documented history of GORD for at least 3 months and endoscopically-proven erosive reflux oesophagitis were treated with dexlansoprazole 60 mg once daily, for 8 weeks to evaluate safety and effectiveness. Patients ranged in age from 12 to 17 years (median age 15 years) with 61% being male. Based on the Los Angeles Classification Grading Scale, 96.8% of the erosive reflux oesophagitis patients had mild erosive reflux oesophagitis (Grades A and B), and 3.2% of patients had moderate to severe erosive reflux oesophagitis (Grades C and D) before treatment. The erosive reflux oesophagitis healing rate in adolescents was 87.9%, which is similar to adults, for up to 8 weeks of treatment<em>.</em></p><p>After the initial 8 weeks of treatment, patients with endoscopically confirmed healed erosive reflux oesophagitis were randomised to receive treatment with dexlansoprazole 30 mg or placebo, once daily for an additional 16 weeks. Eighty-two percent of patients treated with 30 mg of dexlansoprazole remained healed over the four-month treatment period as confirmed by endoscopy versus 58% for placebo.</p><p>During the 16-week maintenance period, the median percentage of 24-hour heartburn-free periods was 86.6% for those receiving dexlansoprazole 30 mg compared to 68.1% for those receiving placebo.</p><p>The results for maintenance of healing and relief of heartburn were similar to adults.</p><p><em>Symptomatic non-erosive GORD</em></p><p>In an uncontrolled, open-label, multi-centre study, 104 adolescents with symptomatic non-erosive<em> </em>GORD were treated with dexlansoprazole 30 mg once daily, for 4 weeks to evaluate safety and<em> </em>effectiveness. Patients had a documented history of GORD symptoms for at least 3 months prior to<em> </em>screening, reported heartburn on at least three out of seven days during screening, and had no<em> </em>oesophageal erosions as confirmed by endoscopy. Patients ranged in age from 12 to 17 years (median<em> </em>age 15 years) with 70% being female. During the 4-week treatment period, the median percentage of<em> </em>24-hour heartburn-free periods was 47.3% which was similar to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The formulation of dexlansoprazole utilising dual delayed release technology results in a dexlansoprazole plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours.</p><p><strong>Absorption</strong></p><p>After oral administration of dexlansoprazole 30 mg or 60 mg to healthy subjects, mean Cmax and AUC values of dexlansoprazole increased approximately dose proportionally. Peak plasma levels occur within 4 to 6 hours.</p><p><strong>Distribution</strong></p><p>Plasma protein binding of dexlansoprazole ranged from 96.1% to 98.8% in healthy subjects and was independent of concentration from 0.01 to 20 mcg per mL. The apparent volume of distribution after multiple doses in symptomatic GORD patients was 40.3 L.</p><p><strong>Biotransformation</strong></p><p>Dexlansoprazole is extensively metabolised in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4. CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates; extensive</p><p>metabolisers (*1/*1), intermediate metabolisers (*1/mutant) and poor metabolisers (mutant/mutant). Systemic exposure of dexlansoprazole is generally higher in intermediate and poor metabolisers. Dexlansoprazole is the major circulating component in plasma, regardless of CYP2C19 metaboliser status. In CYP2C19 intermediate and extensive metabolisers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolisers dexlansoprazole sulfone is the major plasma metabolite.</p><p><strong>Elimination</strong></p><p>Following the administration of dexlansoprazole, no unchanged dexlansoprazole is excreted in urine.</p><p>Following the administration of [<sup>14</sup>C] dexlansoprazole to healthy male subjects, approximately 50.7% of the administered radioactivity was excreted in urine and 47.6% in the faeces. Apparent clearance in healthy subjects was 11.4 to 11.6 L/h, respectively, after 5-days of 30 or 60 mg once daily administration.</p><p><strong>Linearity/non-linearity</strong></p><p>Following a single and multiple daily dexlansoprazole 30 to 120 mg doses to healthy subjects, mean dexlansoprazole Cmax and AUC values increased approximately dose proportionally over the entire dose range. The pharmacokinetics of dexlansoprazole was both dose- and time-independent, with an estimated terminal elimination half-life of approximately 1 to 2 hours. Therefore, little or no active substance accumulation was observed for dexlansoprazole after once daily doses of dexlansoprazole, as evidenced by similar Cmax and AUC values after a single and multiple once-daily doses at steady-state.</p><p><strong>Effect of food</strong></p><p>Instigar can be taken without regard to food or the timing of food. In food-effect studies in healthy subjects receiving dexlansoprazole, increases in Cmax ranged from 12% to 55% and increases in AUC ranged from 9% to 37% under various fed conditions compared to fasting. However, no relevant differences with regard to intragastric pH were observed. An additional study showed that administration of 60 mg dexlansoprazole prior to consumption of breakfast, lunch, dinner or an evening snack did not have an effect on dexlansoprazole exposure, or a clinically relevant effect on 24-hour intragastric pH control.</p><p><strong>Special patient populations</strong></p><p><em>Elderly</em></p><p>In a study of male and female healthy subjects who received a single oral dose of dexlansoprazole 60 mg, the terminal elimination half-life of dexlansoprazole was statistically significantly longer in elderly subjects compared to younger subjects (2.23 and 1.5 hours, respectively). In addition, dexlansoprazole exhibited higher systemic exposure (AUC) in elderly subjects (34.5% higher) than younger subjects. These differences were not clinically relevant. A daily dose of 60 mg should not be exceeded in the elderly unless there are compelling clinical indications.</p><p><em>Renal impairment</em></p><p>Dexlansoprazole is extensively metabolised in the liver to inactive metabolites, and no parent active substance is recovered in the urine following an oral dose of dexlansoprazole. Therefore, the pharmacokinetics of dexlansoprazole are not expected to be altered in patients with renal impairment, and no studies were conducted in subjects with renal impairment (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>In a study of patients with moderately impaired hepatic function who received a single oral dose of dexlansoprazole 60 mg, plasma exposure (AUC) of bound and unbound dexlansoprazole in the hepatic impairment group was approximately 2 times greater compared to subjects with normal hepatic function. This difference in exposure was not due to a difference in protein binding between the two liver function groups. No adjustment for dexlansoprazole is necessary for patients with mild hepatic impairment. dexlansoprazole 30 mg should be considered for patients with moderate hepatic impairment. No studies have been conducted in patients with severe hepatic impairment, the use of dexlansoprazole is not recommended for these patients (see section 4.4).</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of dexlansoprazole were studied in 36 patients with symptomatic GORD aged 12 to 17 years in a multi‑centre study. Patients were randomised to receive dexlansoprazole 30 mg or 60 mg once daily for 7 days. In adolescents, dexlansoprazole mean Cmax was 81% to 105% of the adult mean Cmax value, mean AUC was 78% to 88% of the adult mean AUC value, and mean CL/F was 112% to 132% of the adult mean CL/F value. Overall, dexlansoprazole pharmacokinetics in patients aged 12 to 17 years were similar to those observed in healthy adults.</p><p><em>Gender</em></p><p>In a study of male and female healthy subjects who received a single oral dose of dexlansoprazole 60 mg, females had higher (42.8%) systemic exposure (AUC) than males. No dosage adjustment is necessary in patients based on gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, toxicity to reproduction and development.</p><p>Lansoprazole is a racemic mixture of R- and S-enantiomers. Following administration of lansoprazole in humans and animals, the major component circulating in plasma is dexlansoprazole, the R-enantiomer of lansoprazole. Therefore, the carcinogenic potential of dexlansoprazole was assessed using existing lansoprazole studies.</p><p>In rat carcinogenicity studies, lansoprazole produced dose-related gastric ECL cell hyperplasia and ECL cell carcinoids associated with hypergastrinaemia due to inhibition of acid secretion. Intestinal metaplasia was also observed, as were Leydig cell hyperplasia and benign Leydig cell tumours in the testes. After 18 months of treatment retinal atrophy was observed. This was not observed in monkeys, dogs, or mice.</p><p>In mouse carcinogenicity studies dose-related gastric ECL cell hyperplasia developed as well as liver tumours and adenoma of rete testis.</p><p>The clinical relevance of these findings is unknown.</p><p>Lansoprazole was positive in the Ames test and the <em>in vitro </em>human lymphocyte chromosomal aberration assay. Lansoprazole was not genotoxic in the <em>ex vivo </em>rat hepatocyte unscheduled DNA synthesis (UDS) test, the <em>in vivo </em>mouse micronucleus test, or the rat bone marrow cell chromosomal aberration test.</p><p>Dexlansoprazole was positive in the Ames test and in the <em>in vitro </em>chromosome aberration test using Chinese hamster lung cells. Dexlansoprazole was negative in the <em>in vivo </em>mouse micronucleus test.</p><p>A reproduction study conducted in rabbits at oral dexlansoprazole doses up to approximately 9 times the maximum recommended human dexlansoprazole dose (60 mg per day), based on body surface area (BSA), revealed no evidence of harm to the foetus due to dexlansoprazole. In addition, reproduction studies performed in pregnant rats with oral lansoprazole at doses up to 40 times the recommended human lansoprazole dose, based on BSA, and in pregnant rabbits at oral lansoprazole doses up to 16 times the recommended human lansoprazole dose, based on BSA, revealed no evidence of impaired fertility or harm to the foetus due to lansoprazole.</p><p>Juvenile Animal Studies:</p><p>Lansoprazole studies in juvenile rats (8-week study, 6-week toxicokinetic dose titration study, developmental sensitivity study) covering the paediatric population less than 12 years of age have shown an increased incidence of cardiac valve thickening. The findings reversed or trended towards reversibility after a 4-week drug free recovery period. Juvenile rats younger than postnatal day 21 (age equivalent to approximately 2 years in humans) were more sensitive to the development of cardiac valve thickening. The safety margin to the expected human exposure of dexlansoprazole is in the range of 2 to 3-fold the exposure in juvenile studies based on the AUC at the no-observed-effect level (NOEL) (8-week study, 6-week toxicokinetic dose titration study) or lowest-observed-effect level (LOEL) (developmental sensitivity study).</p><p>The relevance of these findings to paediatric patients less than 12 years of age is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Capsule content:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Silica colloidal anhydrous</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Low-substituted hydroxypropyl cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium carbonate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Methacrylic acid-ethyl acrylate copolymer (1:1)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Methacrylic acid-methyl methacrylate copolymer (1:1)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Methacrylic acid-methyl methacrylate copolymer (1:2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Macrogol 8000</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Polysorbate 80</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sucrose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sugar spheres</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Talc</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Triethyl citrate</p><p><em>Capsule shell:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Carrageenan</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Potassium chloride</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Purified water</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Indigotine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Black iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum-aluminum blisters.</p><p>Pack size: 14 and/or 28 Modified-release hard capsules.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 December 2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>